胍基丁胺在离体豚鼠乳头肌的电生理效应

应用细胞内微电极技术,观察了胍基丁胺（ａｇｍａｔｉｎｅ,ＡＧＭ）对豚鼠乳头肌细胞的电生理效应。结果表明：（１）ＡＧＭ浓度依赖地缩短正常乳头肌动作电位的时程;（２）对部分去极化的乳头肌,ＡＧＭ（１ｍｍｏｌ／Ｌ）除缩短动作电位时程外,还抑制动作电位零相最大上升速度,并降低其幅值和超射值;（３）预先应用一氧化氮合酶抑制剂ＬＮＡＭＥ（０５ｍｍｏｌ／Ｌ）,不能影响ＡＧＭ（１ｍｍｏｌ／Ｌ）的电生理效应;（４）预先应用咪唑啉受体（ｉｍｉｄａｚｏｌｉｎｅｒｅｃｅｐｔｏｒ,ＩＲ）和α２肾上腺素能受体（ａｌｐｈａ２ａｄｒｅｎｅｒｇｉｃｒｅｃｅｐｔｏｒ,α２ＡＲ）拮抗剂ｉｄａｚｏｘａｎ（０１ｍｍｏｌ／Ｌ）,则可完全阻断ＡＧＭ（１ｍｍｏｌ／Ｌ）的电生理效应。以上结果提示,ＡＧＭ对乳头肌的电生理效应似由α２ＡＲ和ＩＲ介导,并与胞浆内Ｃａ２＋减少有关。     

INCREASED PHOSPHORYLATION OF DARPP-32 BY D_1 AGONISTIC ACTION OF l-STEPHOLIDINE IN THE 6-OHDA-LESIONED RAT STRIATUM

为了进一步阐明ＳＰＤ对大鼠纹状体突触后Ｄ１受体的激动作用特性,本文应用反磷酸化在体内测定及放射配体结合方法,分别观察ＳＰＤ对６ＯＨＤＡ损毁大鼠纹状体ＤＡＲＰＰ３２体内磷酸化作用及突触后Ｄ１受体密度的影响。结果表明：皮下给予ＳＰＤ（２０,４０ｍｇ／ｋｇ,２１ｄ）,损毁侧纹状体ＤＡＲＰＰ３２体外［３２Ｐ］的掺入量较健侧下降５０％（Ｐ＜００１）。换言之,损毁侧纹状体内ＤＡＲＰＰ３２的磷酸化程度增加了。然而,ＳＰＤ使损毁导致Ｄ１受体上调的作用减弱（Ｂｍａｘ从３８５０±２６１ｆｍｏｌ／ｍｇ降至３１９７±２０１ｆｍｏｌ／ｍｇ水平）。因此,ＳＰＤ激动Ｄ１受体,使６ＯＨＤＡ损毁大鼠纹状体内ＤＡＲＰＰ３２磷酸化作用加强,而受体密度减少。这是ＳＰＤ调节脑内Ｄ１受体信号转导功能的重要机制。     

头端延髓腹外侧区血管加压素在刺激中脑dPAG区诱发防御性升压反应中的…

雄性Ｓｐｒａｇｕｅ－Ｄａｗｌｅｙ大鼠,用乌拉坦（７００ｍｇ／ｋｇ）和氯醛糖（３０ｍｇ／ｋｇ）腹腔麻醉。在双侧头端延髓腹外侧区（ｒＶＬＭ区）每侧微量注射血管加压素（ＡＶＰ）（１０ｐｍｏｌ／０．１μｌ）可引起平均动脉压（ＭＢＰ）升高,心率（ＨＲ）变化不明显,每侧微量注射ＡＶＰ的Ｖ１受体拮抗剂ｄ（ＣＨ２）５［Ｔｙｒ（Ｍｅ）＾２］ＡＶＰ（０．１ｎｍｏｌ／０．１μｌ）后ＭＢＰ和ＨＲ无明显变化。若预先在ｒＶＬ     

福建产圆斑蝰蛇毒中性磷脂酶A2的降压作用与机理

福建产圆斑蝰蛇毒中性磷脂酶Ａ２（ＰＬＡ２－３）对麻醉Ｗｉｓｔａｒ大鼠、猫和家兔均产生急性降压效应,并具快速耐受性。该降压作用能被吲哚美辛取消。应用放射免疫法测定血浆前列环素（其稳定产物６－ｋｅｔｏ－ＰＧＦｌａ）含量,与给药前相比,降压高峰时血浆６－ｋｅｔｏ－ＰＧＦＩｌａ含量增高。离体入胃网膜动脉条实验观察到,ＰＬＡ２－３呈剂量依赖性降低入胃网膜动脉条静息张力;对预先用去甲肾上腺素或５－羟色胺收缩的人胃网膜动脉条也具松弛作用。结果表明该ＰＬＡ２降压机制与前列环素（ＰＧＩ２）的释放和外周血管扩张有关。     

兔迷走复合区内微量注射TRH对奥迪氏括约肌肌电的影响及传出途径分析

目的和方法：本工作旨在研究免迷走复合区（ＤＶＣ）内ＴＲＨ对奥迪氏括约肌（ＳＯ）肌电的调节作用及外周途径。结果：（１）ＤＶＣ内注射ＴＲＨ（０．８ｎｍｏｌ,１μｌ）后,慢波电位（ＳＷ）频率不变,但锋电位频率（ＦＳＰＳＯ）及幅度（ＡＳＰＳＯ）、锋电位发生率（ＩＳＰ）明显增加．（２）ＤＶＣ内分别注射不同剂量ＴＲＨ（０．１３,０．２５,０．５０,０．８０,１．３０ｎｍｏｌ,１μｌ）后,各剂量ＴＲＨ均能引起ＦＳＰＳＯ增加。随注射剂量的增加,ＳＯ反应强度和持续时间均增加,呈现明显的剂量反应关系。（３）ＤＶＣ内注射ＴＲＨ兴奋ＦＳＰＳＯ的效应可被静脉注射阿托品（０．２ｍｇ／ｋｇ）或迷走神经切断完全阻断,但不能被静脉注射酚妥拉明（１．５ｍｇ／ｋｇ）、心得安（１．５ｍｇ／ｋｇ）或脊髓切断术所阻断。结论：ＤＶＣ内ＴＲＨ可能对ＳＯ肌电有重要的调节作用,这种作用是通过迷走神经及外周Ｍ受体介导。     

肾动脉内注射内皮素—1对麻醉大鼠肾神经传入放电的影响

本实验旨在观察肾动脉内注射ＥＴ－１对麻醉大鼠血压（ＢＰ）、心率（ＨＲ）和肾神经传入放电（ＡＲＮＡ）的影响,以及ＥＴＡ受体阻断剂ＢＱ－１２３和硝苯吡啶（Ｎｉｆ）对ＥＴ生物学效应的拮抗作用。结果如下：（１）肾动脉注射ＥＴ－１（１μｇ／ｋｇ）后,平均动脉压（ＭＡＰ）先有短暂的降低（由１３．７７±０．１３ｋＰａ降至１０．２±１．１２ｋＰａ）,随后为较显著的持久增高,增值达３．４４±１．６０ｋＰａＰ＜０．００１）,ＨＲ无明显变化,ＡＲＮＡ增加１０８．３３±１６．６７％（Ｐ＜０．００１）。（２）肾动脉内注射ＥＴＡ受体选择性拮抗剂ＢＱ－１２３（１５０μｇ／ｋｇ）,ＥＴ－１的上述效应即被拮抗。与ＥＴ组相比差异非常显著（Ｐ＜０．００１）。（３）肾动脉内注射二氢吡啶敏感性Ｌ－型钙通道阻断剂Ｎｉｆ（０．１ｍｇ／ｋｇ）,也可明显抑制ＥＴ－１的上述效应,与ＥＴ组相比差异十分显著（Ｐ＜０．００１）。以上结果表明：肾动脉内注射ＥＴ－１引起的麻醉大鼠ＭＡＰ增高和ＡＲＮＡ积分增加的作用,可能是由ＥＴＡ受体介导的,其作用的细胞机制可能在于胞内钙超载     

硝基左旋精氨酸对睡眠抑制作用的机制研究

本文观察了硝基左旋精氨酸（Ｌ－ＮＮＡ,５０ｍｇ／ｋｇ,ｉｐ）和Ｌ－精氨酸（Ｌ－ａｒｇ,１１０ｍｇ／ｋｇ,ｉｐ）对慢性植入电极的大鼠睡眠－觉醒周期的影响及中缝核５－羟色胺（５－ＨＴ）神经元免疫阳性反应的变化。结果表明：Ｌ－ＮＮＡ显著抑制慢波睡眠和快眼动睡眠,使平均动脉压（ＭＡＰ）升高。Ｌ－ａｒｇ则使ＭＡＰ显著降低,对睡眠无明显影响。预先给予Ｌ－ａｒｇ可逆转Ｌ－ＮＮＡ的效应。腹腔给予Ｌ－ＮＮＡ后２ｈ,     

降钙素基因相关肽拮抗内皮素的致心律失常作用

本工作在麻醉大鼠冠状动脉口注射内皮素１（ＥＴ１）９００ｐｍｏｌ／ｋｇ能引起室性早搏（ＰＶＣ）、室速（ＶＴ）、室颤（ＶＦ）等严重心律失常,心律失常评分（ＡＳ）为５．６±１．０;冠状动脉口单独注射降钙素基因相关肽（ＣＧＲＰ）３００－１２００ｐｍｏｌ／ｋｇ仅引起血压一过性下降,此后逐渐恢复,无心律失常发生,心律失常评分为０。用ＣＧＲＰ３００ｐｍｏｌ／ｋｇ预处理后再注射ＥＴ１９００ｐｍｏｌ／ｋｇ,心律失常发生率减少,严重程度降低,ＡＳ为１．６±１．６。ＣＧＲＰ１２００ｐｍｏｌ／ｋｇ＋ＥＴ１组心律失常评分显著低于ＥＴ１对照组（Ｐ＜０．０１）。本实验结果表明,ＣＧＲＰ的抗心律失常作用很可能有部分是通过拮抗内皮素的致心律失常作用来实现的。     

磷脂酶A2在内毒素致大鼠肺损伤中的作用

大鼠静脉注射大肠杆茵内毒素（３０ｍｇ／ｋｇ）后３ｈ肺血管外水量和支气管肺泡灌洗液中蛋白浓度明显增加,表明发生了通透性肺水肿;同时血清和支气管肺泡灌洗液中磷脂酶Ａ２（ＰＬＡ２）活性升高,且ＰＬＡ,活性的升高与肺血管外水量的增加呈显著正相关。预先给予ＰＬＡ２抑制剂对溴苯酰基溴可抑制内毒素引起的ＰＬＡ２活性升高和通透性肺水肿。提示ＰＬＡ２介导了内毒素引起的肺损伤。     

左旋千金藤啶碱D1激动—D2阻滞作用引起伏核双相放电活动的电生理研究

为确定左旋千金藤啶碱（ＳＰＤ）对中脑边缘ＤＡ神经系统的作用特性,本研究采用细胞外记录的电生理学方法,观察微电泳和尾静脉给药对６－ＯＨＤＡ损毁及未损毁大鼠的伏核（ＮＡｃ）单位放电的影响。结果显示：ＳＰＤ累积给药（０．０２－２ｍｇ／ｋｇ,ｉｖ）可诱发ＮＡｃ神经元双相放电特征,即小剂量抑制、大剂量兴奋。预先给予Ｄ２受体拮抗剂ｓｐｅｐｅｒｏｎｅ,ＳＰＤ则仅产生兴奋效应,并被Ｄ１拮抗剂ＳＣＨ－２３３９０所翻     

区域性血管床对局部注射胍丁胺的不同反应

在66只麻醉大鼠,分别采用后肢、肾脏和肠系膜动脉在体恒流灌注法,观察了向灌注环路中直接注射胍丁胺（agmatine,AGM）的血管效应,以所引起的灌流压增减反映血管的收缩和舒张。所得结果如下：（1）不同剂量的AGM（0.1、0.5、1mg/kg）注射于股部灌注环路时,可剂量依赖性地增高后肢血管的灌流压。无论预先注射咪唑啉受体(imidazoline receptor,IR）和α2－肾上腺素能受体阻断剂（α2－adrenergic receptor,α2－AR）idazoxan(0.5mg/kg）或注射α2-肾上腺素能受体阻断剂yohimbine(1mg/kg）均可完全阻抑上述AGM的效应。（2）向肾血管灌注环路中直接注射AGM也可剂量依赖性地增高肾血管的灌流压,需特别指出的是：大剂量AGM（1mg/mg）引起肾血管双相的灌注压增高,此效应可被idazoxan完全阻断。而在预先应用yohimbine后,再注射AGM则引起肾血管灌流压降低。（3）在肠系膜血管灌流环路中注射AGM可剂量依赖性地降低其灌流压。此效应可被idazoxan(0.5mg/kg）完全阻断,而yohimbine(1mg/kg）对此无作用。根据上述结果得出的结论是,AGM对后肢、肾脏和肠系膜血管床的血管紧张性具有不同的作用。     

胍丁胺对Dahl盐敏感型高血压大鼠和Dahl盐抵抗型大鼠血流动力学的影响

在麻醉Dahl盐敏感型(DS)高血压大鼠和Dahl盐抵抗型(DR)正常血压大鼠,研究了静注胍丁胺(agmatine,AGM)对血流动力学的影响.结果显示(1)静注AGM(1,10,20mg/kg)可剂量依赖性地降低DS和DR大鼠的HR,MAP,LVP,±LVdp/dtmax,CI和TPRI.在DS高血压大鼠,MAP,LVP,±LVdp/dtmax和TPRI较DR正常血压大鼠下降幅度要大;而HR和CI在两种大鼠下降幅度无差异.需特别提出的是,DS高血压大鼠在静注高剂量AGM(20mg/kg)后,各项血流动力学指标出现先降低而后升高的现象,这一结果在DR正常血压大鼠并未出现.(2)预先静注咪唑啉受体(IR)和α2-肾上腺素能受体阻断剂(α2-AR)idazoxan(2.5mg/kg)可部分阻抑AGM的血流动力学效应.(3)预先静注α2-肾上腺素能受体阻断剂yohimbine(4mg/kg)同样可部分阻抑AGM的效应.(4)预先静注咪唑啉受体(I1)和α2-肾上腺素能受体阻断剂efaroxan(2.5mg/kg)则完全阻断AGM的血流动力学效应.以上结果表明,AGM可显著降低麻醉DR和DS大鼠的HR,MAP,LVP,±LVdp/dtmax,CI和TPRI;此效应似主要由I1-IR所介导,并有I2-IR和α2-AR参与.     

Investigation on the mechanism involved in the effects of agmatine on ethanol-induced gastric mucosal injury in rats

Effects of agmatine, an endogenous metabolite formed by decarboxylation of L-arginine, on ethanol-induced gastric mucosal injury were investigated in rats. Agmatine at 1 and 10 mg/kg i.p doses significantly increased ethanol-induced gastric mucosal injury. This effect of agmatine was abolished completely by pretreatment with idazoxan, an imidazoline receptor-antagonist and alpha2 receptor- antagonist, (0.5 mg/kg i.p), partly by yohimbine, an alpha2 receptor- antagonist, (1 mg/kg i.p) but not by L-arginine, a precursor of nitric oxide, (500 mg/kg i.p). Our results suggest that agmatine had a potent ulcerogenic effect mediated, at least in part, by both alpha2-adrenoceptors and imidazoline receptors.     

Effects of imidazolines on neurogenic contraction in isolated urinary bladder detrusor strips from rabbit

Moxonidine and clonidine, which are imidazoline compounds, are sympathetic modulators used as centrally acting antihypertensive drugs. Moxonidine, clonidine, and agmatine produce extensive effects in mammalian tissues via imidazoline recognition sites (or receptors) or α(2)-adrenoceptors. To investigate the effects of imidazolines on the function of the urinary bladder, we tested the effects of moxonidine, clonidine, and agmatine on the neurogenic contraction induced by electric field stimulation, and on the post-synaptic receptors in isolated urinary bladder detrusor strips from rabbit. Both moxonidine at 1.0-10.0?μmol/L and clonidine at 0.1-10.0?μmol/L inhibited electric-field-stimulation-induced contraction in a concentration-dependent manner, but not agmatine (10.0-1000.0?μmol/L). Both moxonidine and clonidine failed to affect carbachol or adenosine-triphosphate-induced contractions; however, 1000.0?μmol/L agmatine significantly increased these contractions. Our study indicates that (i) moxonidine and clonidine produce a concentration-dependent inhibition of the neurogenic contractile responses to electric field stimulation in isolated detrusor strips from male New Zealand rabbits; (ii) post-synaptic muscarinic receptor and purinergic receptor stimulation are not involved in the responses of moxinidine and clonidine in this study; (iii) the inhibitory effects of these agents are probably not mediated by presynaptic imidazoline receptors.     

Methylation of imidazoline related compounds leads to loss of α₂-adrenoceptor affinity. Synthesis and biological evaluation of selective I₁ imidazoline receptor ligands

Methylated analogues of imidazoline related compounds (IRC) were prepared; their abilities to bind I(1) imidazoline receptors (I(1)Rs), I(2) imidazoline binding sites (I(2)BS) and α(2)-adrenoceptor subtypes (α(2)ARs) were assessed. Methylation of the heterocyclic moiety of IRC resulted in a significant loss of α(2)AR affinity. Amongst the selective ligands obtained, LNP 630 (4) constitutes the first highly selective I(1)R agent showing hypotensive activity after intravenous administration.     

Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting the NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-κB pathway

Dexmedetomidine (DEX) prevents kidney damage caused by sepsis, but the mechanism of this effect remains unclear. In this study, the protective molecular mechanism of DEX in lipopolysaccharide (LPS)-induced acute kidney injury was investigated and its potential pharmacological targets from the perspective of inhibiting oxidative stress damage and the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome activation. Intraperitoneal injection of DEX (30 μg/kg) significantly improved LPS (10 mg/kg) induced renal pathological damage and renal dysfunction. DEX also ameliorated oxidative stress damage by reducing the contents of reactive oxygen species, malondialdehyde and hydrogen peroxide, and increasing the level of glutathione, as well as the activity of superoxide dismutase and catalase. In addition, DEX prevented nuclear factor-kappa B (NF-κB) activation and I-kappa B (IκB) phosphorylation, as well as the expressions of NLRP3 inflammasome-associated protein and downstream IL-18 and IL-1β. The messengerRNA (mRNA) and protein expressions of toll-like receptor 4 (TLR4), NADPH oxidase-4 (NOX4), NF-κB, and NLRP3 were also significantly reduced by DEX. Their expressions were further evaluated by immunohistochemistry, yielding results were consistent with the results of mRNA and protein detection. Interestingly, the protective effects of DEX were reversed by atipamezole-an alpha 2 adrenal receptor (α₂AR) inhibitor, whereas idazoxan-an imidazoline receptor (IR) inhibitor failed to reverse this change. In conclusion, DEX attenuated LPS-induced AKI by inhibiting oxidative stress damage and NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-κB pathway, mainly acting on the α₂AR rather than IR.     

Electrophysiological effects of agmatine on human atrial fibers

The objective of the present study was to study the electrophysiological effects of agmatine on human atrial fibers obtained at cardiac surgery using standard microelectrode techniques. Agmatine (1 to approximately 10 mM) decreased the action potential amplitude (APA), maximum upstroke velocity of phase 0 depolarization (Vmax), velocity of diastolic (phase 4) depolarization (VDD), rate of pacemaker firing (RPF), and action potential duration at 50 and 90% of repolarization (APD(50-90)) in a concentration-dependent manner. Pretreatment with N(G)-nitro-L-arginine methyl ester (L-NAME, 0.5 mM), a NOS inhibitor, did not affect the electrophysiological effects of agmatine (5 mM) on human atrial fibers. The effects of agmatine (5 mM) could be blocked completely by pretreatment with idazoxan (0.1 mM), an alpha-2 adrenergic receptor (alpha2-AR) and imidazoline receptor (IR) antagonist. All these results indicate that the effects of agmatine on human atrial fibers are likely due to a decrease of intracellular calcium mediated by IR and/or alpha2-AR.     

Central and peripheral alpha adrenergic activity of imidazoline derivatives

Intravenous injection of a number of imidazoline derivatives into rats induced an increase in blood pressure due to peripheral alpha adrenergic receptor stimulation. Some of these compounds, however, caused a secondary, long lasting decrease which was caused by central nervous system alpha adrenergic receptor stimulation. This central hypotensive action was only observed in the case of 2-amino-imidazolines such as clonidine, tramazoline and St 600, a clonidine analogue. Imidazolines lacking the nitrogen between the imidazoline and the benzene or naphtalene group such as oxymetazoline, xylometazoline and naphazoline were found to exert no central hypotensive action.Within the series of 2-amino-imidazolines lipid solubility turned out to be a major factor in the potency of a drug's central hypotensive action.Oxymetazoline — peripherally a very potent alpha adrenergic receptor stimulating agent — did not even cause hypotension when injected into the anterior hypothalamus, a brain structure where alpha adrenergic receptors mediating depressor effects have been localized. These data show that the hypothalamic alpha adrenergic receptors differ from peripheral alpha receptors and that only imidazolines with 2-amino substitution show affinity for these central hypotensive alpha adrenergic receptors.     

Hypotensive activity of novokinin, a potent analogue of ovokinin(2-7), is mediated by angiotensin AT(2) receptor and prostaglandin IP receptor

Novokinin (Arg-Pro-Leu-Lys-Pro-Trp) is a potent hypotensive peptide previously designed based on the structure of ovokinin(2-7) (Arg-Ala-Asp-His-Pro-Phe), a vasorelaxing and hypotensive peptide derived from ovalbumin. Novokinin exhibited an affinity for the angiotensin AT(2) receptor (Ki=7.35 microM). Novokinin significantly lowered systolic blood pressure at a dose of 0.03 and 0.1 mg/kg after intravenous and oral administration, respectively, in spontaneously hypertensive rats (SHRs), and the hypotensive activity was blocked by PD123319, an antagonist of the AT(2) receptor. Novokinin lowered blood pressure in C57BL/6J mice after oral administration at a dose of 50 mg/kg. However, in AT(2) receptor-deficient mice, novokinin did not reduce blood pressure. These results demonstrate that the hypotensive activity of novokinin is mediated by the AT(2) receptor. The hypotensive activity of novokinin in SHRs was completely blocked by indomethacin and CAY10441, an inhibitor of cyclooxygenase and an antagonist of the prostaglandin IP receptor, respectively. These suggest that the hypotensive activity is mediated by prostacyclin and the IP receptor downstream of the AT(2) receptor.     

Uptake of Agmatine into Rat Brain Synaptosomes: Possible Role of Cation Channels

Abstract: Agmatine (decarboxylated arginine), an endogenous ligand for imidazoline receptors, has been identified in brain where it is synthesized from arginine by arginine decarboxylase. Here we report a mechanism for the transport of agmatine into rat brain synaptosomes. The uptake of agmatine was energy- and temperature-dependent and saturable with a K _m of 18.83 ± 3.31 m M and a V _max of 4.78 ± 0.67 nmol/mg of protein/min. Treatment with ouabain (Na⁺,K⁺-ATPase inhibitor) or removal of extracellular Na⁺ did not attenuate the uptake rate. Agmatine transport was not inhibited by amino acids, polyamines, or monoamines, indicating that the uptake is not mediated by any amino acid, polyamine, or monoamine carriers. When we examined the effects of some ion-channel agents on agmatine uptake, only Ca²⁺-channel blockers inhibited the uptake, whereas a reduction in extracellular Ca²⁺ increased it. In addition, some imidazoline drugs, such as idazoxan and phentolamine, were strong noncompetitive inhibitors of agmatine uptake. Thus, a selective, Na⁺-independent uptake system for agmatine exists in brain and may be important in regulating the extracellular concentration of agmatine.